cagrilintide vs eloralintide

cagrilintide (B-tier) vs eloralintide (B-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

cagrilintide · tier B

novo's long-acting amylin analog. 11.8% standalone weight loss in the phase-3 REDEFINE-1 trial (10.8% earlier in phase 2). the filed product is the cagrisema combo, not the monotherapy.

a long-acting amylin analog from novo. the standalone hit 11.8% weight loss in the phase-3 REDEFINE-1 trial (10.8% in phase 2 before that). the program novo actually filed with the FDA is the cagrisema combo, not cagrilintide alone.

10.8% Lau 2021 phase 2 · half-life ~7 days (once-weekly dosing) · weight loss

eloralintide · tier B

a weight-loss drug eli lilly is still testing, given in trials as a once-a-week injection under the skin. it copies amylin, the fullness hormone the pancreas releases with insulin at a meal. 20% weight loss at 48 weeks in one 263-person phase 2, and 64.3% nausea in the fixed 6 mg arm. five phase 3 trials are enrolling and none reads out before 2028.

a weight-loss drug eli lilly has in development, given as a once-a-week injection under the skin, which works by turning up the body's own after-meal fullness signal. formally an amylin receptor agonist, code LY3841136. one published 48-week phase 2 (NCT06230523, n=263) produced up to 20% mean weight loss with no incretin anywhere in the molecule. eli lilly sponsors every trial on the record, the phase 3 programme has yet to report, and nausea reached 64.3% in the fixed 6 mg arm, which the selectivity pitch did not predict.

20% mean weight change in the 9 mg phase 2 arm · half-life 310 to 366 h (12.9 to 15.3 days) across 0.4 to 12 mg in phase 1 · weight loss

at a glance

• cagrilintide: tier B · 10.8% Lau 2021 phase 2
• eloralintide: tier B · 20% mean weight change in the 9 mg phase 2 arm

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.